Month: October 2022
-
Drug Licensed for Precision Autism Spectrum Therapies
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress.
-
Infographic – Sharp Drop in Q3 Venture Funds
Total venture investing worldwide dropped to $81 billion in July to September 2022, a decline of $40 billion or one-third compared to the second quarter of the year.
-
RNA Cancer Immunotherapy Shown Feasible in Preclinical Test
Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors.
-
Nasal Spray Vaccines Get CEPI, NIH Funding
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea.
-
Yom Kippur 5783
Regular posting will resume tomorrow, Thursday, 6 Oct.
-
Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test
A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria.
-
Patent Issued for Crispr-Edited Viruses in Microbiome
A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments.
-
Infographic – Biotech Index Q3 Rollercoaster
For the year-to-date, as noted in today’s chart, NBI shows a general decline, losing more than one-fifth of its value since January.